Tryptyr Solution
NDC 0065-8595
Product Information
Tryptyr (acoltremon) is a NDA-approved product labeled by Alcon Laboratories, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a solution for ophthalmic; topical administration. This product entry covers the primary NDC 0065-8595 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
- Ophthalmic - Administration to the external eye.
- Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 0065-8595?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ACOLTREMON (UNII: 1L7BVT4Z4Z)
- ACOLTREMON (UNII: 1L7BVT4Z4Z) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- POLYOXYL 35 CASTOR OIL (UNII: 6D4M1DAL6O)
- SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE (UNII: 5QWK665956)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- HYPROMELLOSE 2906 (4000 MPA.S) (UNII: 5EYA69XGAT)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2716821 - acoltremon 0.003 % Ophthalmic Solution
- RxCUI: 2716821 - acoltremon 0.03 MG/ML Ophthalmic Solution
- RxCUI: 2716826 - TRYPTYR 0.003 % Ophthalmic Solution
- RxCUI: 2716826 - acoltremon 0.03 MG/ML Ophthalmic Solution [Tryptyr]
- RxCUI: 2716826 - Tryptyr 0.003 % Ophthalmic Solution
* Please review the full disclaimer at the bottom of this page.